SynthesisAmerican journal of clinical dermatology2026
Outcomes and Predictors of Sustained Response After Dose Tapering of Targeted Therapies in Moderate-to-Severe Atopic Dermatitis: A Systematic Review.
Synthesis in American journal of clinical dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundModerate-to-severe atopic dermatitis (AD) often requires prolonged systemic therapy. As disease control is achieved, optimizing dose tapering and identifying factors associated with sustained response are increasingly relevant.
objectiveThe aim was to identify factors associated with maintained disease control following dose tapering of biologics and small-molecule inhibitors used for AD.
methodsA systematic review was conducted in accordance with Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines. MEDLINE, Embase, and the Cochrane Library were searched from 2010 to present, along with manual reference screening. Studies evaluating dose tapering or withdrawal of dupilumab, tralokinumab, lebrikizumab, abrocitinib, baricitinib, or upadacitinib were included. Extracted data included study design, patient characteristics, tapering or withdrawal strategies, and follow-up duration. Outcomes of interest were sustained response, relapse rates, and predictors of long-term disease control.
resultsNineteen studies (4375 patients) were included. Sustained response rates post-tapering varied across abrocitinib (0-60%), baricitinib (45-61%), dupilumab (30-100%), lebrikizumab (67-82%), tralokinumab (25-50%), and upadacitinib (47-61%). Lower baseline disease activity and early clinical improvement were frequently identified as potential predictors of durability. For dupilumab, older age, lower body mass index (BMI), and prurigo nodularis phenotype were associated with sustained response in selected cohorts. For tralokinumab, longitudinal stability across multiple visits outperformed single-time-point assessments. Abrocitinib outcomes favored milder disease without allergic comorbidities, whereas upadacitinib showed higher relapse rates after withdrawal.
conclusionsIn selected patients with moderate-to-severe AD achieving stable disease control, dose tapering appeared to preserve efficacy more frequently than abrupt withdrawal, although response rates and durability varied across therapeutic classes, study designs, and outcome definitions. Predictors of sustained response were drug specific, and longer prospective studies are needed to inform individualized tapering strategies.
Identifiers
42873475What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.